Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.

Xu C, Ravva P, Dang JS, Laurent J, Adessi C, McIntyre C, Meneses-Lorente G, Mercier F.

Cancer Chemother Pharmacol. 2018 Jun 18. doi: 10.1007/s00280-018-3621-9. [Epub ahead of print]

PMID:
29915982
2.

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.

Moisan A, Michielin F, Jacob W, Kronenberg S, Wilson S, Avignon B, Gérard R, Benmansour F, McIntyre C, Meneses-Lorente G, Hasmann M, Schneeweiss A, Weisser M, Adessi C.

Mol Cancer Ther. 2018 Jul;17(7):1464-1474. doi: 10.1158/1535-7163.MCT-17-1268. Epub 2018 Apr 13.

PMID:
29654069
3.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.

PMID:
29349598
4.

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE.

Clin Cancer Res. 2017 Oct 15;23(20):6128-6137. doi: 10.1158/1078-0432.CCR-17-0311. Epub 2017 Jul 21.

5.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

6.

Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.

Meneses-Lorente G, McIntyre C, Hsu JC, Thomas M, Jacob W, Adessi C, Weisser M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1239-1247. doi: 10.1007/s00280-017-3328-3. Epub 2017 May 11.

PMID:
28497320
7.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

8.

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.

PMID:
26179200
9.

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Meneses-Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, Thomas M, Bossenmaier B.

Cancer Chemother Pharmacol. 2015 Apr;75(4):837-50. doi: 10.1007/s00280-015-2697-8. Epub 2015 Feb 22.

10.

Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion.

Siebel AL, Natoli AK, Yap FY, Carey AL, Reddy-Luthmoodoo M, Sviridov D, Weber CI, Meneses-Lorente G, Maugeais C, Forbes JM, Kingwell BA.

Circ Res. 2013 Jul 5;113(2):167-75. doi: 10.1161/CIRCRESAHA.113.300689. Epub 2013 May 15.

PMID:
23676183
11.

Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

Kilburn LB, Kocak M, Schaedeli Stark F, Meneses-Lorente G, Brownstein C, Hussain S, Chintagumpala M, Thompson PA, Gururangan S, Banerjee A, Paulino AC, Kun L, Boyett JM, Blaney SM.

Neuro Oncol. 2013 Jun;15(6):759-66. doi: 10.1093/neuonc/nos315. Epub 2013 Apr 16.

12.

Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.

Derks M, Kawamura H, Abt M, Meneses-Lorente G, Phelan M, Ishikawa T.

Clin Ther. 2011 Jun;33(6):754-65. doi: 10.1016/j.clinthera.2011.05.046.

PMID:
21704240
13.

No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.

Derks M, Abt M, Parr G, Meneses-Lorente G, Young AM, Phelan M.

Expert Opin Investig Drugs. 2010 Oct;19(10):1135-45. doi: 10.1517/13543784.2010.509342.

PMID:
20738227
14.

Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.

Derks M, Abt M, Mwangi A, Meneses-Lorente G.

Eur J Clin Pharmacol. 2010 Aug;66(8):775-83. doi: 10.1007/s00228-010-0841-2. Epub 2010 Jun 3.

PMID:
20521033
15.

Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.

Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, Parr G.

J Clin Pharmacol. 2010 Oct;50(10):1188-201. doi: 10.1177/0091270009358709. Epub 2010 May 20.

PMID:
20489031
16.

Utility of long-term cultured human hepatocytes as an in vitro model for cytochrome p450 induction.

Meneses-Lorente G, Pattison C, Guyomard C, Chesné C, Heavens R, Watt AP, Sohal B.

Drug Metab Dispos. 2007 Feb;35(2):215-20. Epub 2006 Nov 8.

17.

N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.

Elliott JM, Carling RW, Chambers M, Chicchi GG, Hutson PH, Jones AB, MacLeod A, Marwood R, Meneses-Lorente G, Mezzogori E, Murray F, Rigby M, Royo I, Russell MG, Sohal B, Tsao KL, Williams B.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5748-51. Epub 2006 Sep 6.

PMID:
16950620
18.

N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.

Elliott JM, Carling RW, Chicchi GG, Crawforth J, Hutson PH, Jones AB, Kelly S, Marwood R, Meneses-Lorente G, Mezzogori E, Murray F, Rigby M, Royo I, Russell MG, Shaw D, Sohal B, Tsao KL, Williams B.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5752-6. Epub 2006 Sep 6.

PMID:
16950617
19.

Identification of early proteomic markers for hepatic steatosis.

Meneses-Lorente G, Watt A, Salim K, Gaskell SJ, Muniappa N, Lawrence J, Guest PC.

Chem Res Toxicol. 2006 Aug;19(8):986-98.

PMID:
16918237
20.

A quantitative high-throughput trapping assay as a measurement of potential for bioactivation.

Meneses-Lorente G, Sakatis MZ, Schulz-Utermoehl T, De Nardi C, Watt AP.

Anal Biochem. 2006 Apr 15;351(2):266-72. Epub 2006 Jan 30.

PMID:
16473319
21.

A proteomic investigation of drug-induced steatosis in rat liver.

Meneses-Lorente G, Guest PC, Lawrence J, Muniappa N, Knowles MR, Skynner HA, Salim K, Cristea I, Mortishire-Smith R, Gaskell SJ, Watt A.

Chem Res Toxicol. 2004 May;17(5):605-12.

PMID:
15144217
22.

An evaluation of a low-density DNA microarray using cytochrome P450 inducers.

Meneses-Lorente G, de Longueville F, Dos Santos-Mendes S, Bonnert TP, Jack A, Evrard S, Bertholet V, Pike A, Scott-Stevens P, Remacle J, Sohal B.

Chem Res Toxicol. 2003 Sep;16(9):1070-7.

PMID:
12971794
23.

Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis.

Knowles MR, Cervino S, Skynner HA, Hunt SP, de Felipe C, Salim K, Meneses-Lorente G, McAllister G, Guest PC.

Proteomics. 2003 Jul;3(7):1162-71.

PMID:
12872217
24.

Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray.

de Longueville F, Surry D, Meneses-Lorente G, Bertholet V, Talbot V, Evrard S, Chandelier N, Pike A, Worboys P, Rasson JP, Le Bourdellès B, Remacle J.

Biochem Pharmacol. 2002 Jul 1;64(1):137-49.

PMID:
12106614
25.

CYP isoform induction screening in 96-well plates: use of 7-benzyloxy-4-trifluoromethylcoumarin as a substrate for studies with rat hepatocytes.

Price RJ, Surry D, Renwick AB, Meneses-Lorente G, Lake BG, Evans DC.

Xenobiotica. 2000 Aug;30(8):781-95.

PMID:
11037111
26.

Rapid determination of rat hepatocyte mRNA induction potential using oligonucleotide probes for CYP1A1, 1A2, 3A and 4A1.

Surry DD, Meneses-Lorente G, Heavens R, Jack A, Evans DC.

Xenobiotica. 2000 May;30(5):441-56.

PMID:
10875679
27.

High throughput ribonuclease protection assay for the determination of CYP3A mRNA induction in cultured rat hepatocytes.

Surry DD, McAllister G, Meneses-Lorente G, Evans DC.

Xenobiotica. 1999 Aug;29(8):827-38.

PMID:
10553723

Supplemental Content

Loading ...
Support Center